Specifically, HMGB1, along with calreticulin, is known to be pivotal for immunogenic cell death (ICD) in CRC treated with oxaliplatin by triggering Toll-like receptor 4 in the immune compartment [112]. Here, CALR is linked to colorectal carcinoma.